OVARIAN CANCER

(1), ovarian cancer-chemotherapy drug commonly used drug <BR> melphalan (PAM) 0.2 ^ / ㎏ d, oral, 4 ~ for a course on the 5th, rest four to six weeks after duplication. Thiotepa (161-169) 10 ^ / times, intramuscular or intravenous injection, used five times, every other day to once a total of 300 ~ 500 days for an induction course. 6 to 8 weeks under the condition repeat. Cyclophosphamide (CTX) 50 ~ 100 ^ / day, oral, 7 ~ 10 Tianyi treatment, two weeks after duplication. Or 400 ^ / day, intravenous, oral to four days. Adriamycin (ADM) 50 ~ 70 ^ / ㎡, intravenous injection. Every three weeks.
(2), and malignant ovarian tumor joint chemical treatment of ovarian cancer chemotherapy are better response. In recent years the chemical treatment of tumors faster progress in the treatment of ovarian cancer Habitat has an important place to improve the treatment of ovarian cancer play a positive role as a surgical adjuvant therapy, commonly used in the preoperative, intraoperative and postoperative, but often require a longer period of intermittent medication, and the human body toxicity also sometimes larger. In most cases, it is difficult to ovarian cancer surgery primary tumor and metastasis consider chemical treatment based treatment.

Tags: body, cancer, cases, chemotherapy, days, drug, eat, injection, intravenous, malignant, metastasis, ovarian, positive, response, surgery, surgical, therapy, time, toxicity, treatment, tumor, tumors

A large number of pre-clinical data and the right abdominal anatomy, physiology and biology of ovarian cancer have suggested that understanding, abdominal local cytotoxic drug treatment for ovarian cancer is very reasonable. Intraperitoneal chemotherapy Phase I clinical trial confirmed the chemotherapy drugs and intraperitoneal chemotherapy safety of the technology itself, confirmed the intraperitoneal chemotherapy in the pharmacokinetic advantages.

In some multi-center Phase II clinical trials, surgical results confirmed that about 20% to 40% of second-tier category to cisplatin-based chemotherapy in patients with celiac complete remission, the part of the residual cancer patients <0.5 cm before  acceptable to platinum-based chemotherapy effective systemic System .

Tags: abdominal, administration, age, cancer, carboplatin, cause, chemotherapy, cisplatin, clinical, days, drug, drugs, eat, group, incidence, infusion, injection, intraperitoneal, intravenous, ovarian, paclitaxel, pain, patients, rate, reduce, residual, second, study, surgical, survival, taxol, therapy, time, toxicity, treatment, tumor

Ovarian cancer

Tags: age, annex, blood, body, cancer, cases, cell, cells, chemotherapy, clinical, cyst, cystic, diagnosis, drug, drugs, early, eat, examination, fat, mass, method, ovarian, pain, patients, pelvic, poor, prognosis, reduce, resection, study, surgical, symptoms, therapy, time, toxicity, treatment, tumor, tumors, women

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

Cytoreductive surgery in the treatment of ovarian cancer Comprehensive Application and prospects

Foreign Medical Obstetrics and Gynecology volumes in 1999 Vol 26 No. 2

Tianjin Medical University General Hospital of Obstetrics and Gynecology (300,052) of the new QU (Summary) if Mi (revision)

Abstract <BR> since the 1980s, complete cytoreductive surgery to cisplatin-based combination chemotherapy for ovarian cancer as a conventional model, cytoreductive surgery is the complete impact of the prognosis of patients with one of the important factors for recurrent ovarian cancer once again cytoreductive surgery still some value , but to improve the survival rate of patients is more important to be effective after chemotherapy treatment as a necessary complement. Early ovarian cancer retroperitoneal lymph node dissection is reasonable and significance of the still controversial.

Tags: abdominal, age, annex, anti, bleeding, blood, cancer, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, diagnosis, drug, drugs, early, eat, ert, exploration, gene, growth, incidence, increased, intraperitoneal, intravenous, life, lymph, malignant, metastasis, metastatic, method, mutation, node, ovarian, p53, patients, pelvic, physical, poor, positive, prognosis, quality, rate, reduce, resection, residual, response, second, staging, study, surgery, surgical, survival, therapy, time, toxicity, treatment, tumor, tumors

Ovarian cancer mortality first Habitat gynecologic malignancies, as misprision of onset, 70% of patients when treatment is already advanced. Surgery and chemotherapy comprehensive application is the treatment of advanced ovarian cancer, especially epithelial ovarian cancer therapy of choice. Platinum drug resistance ovarian cancer is the main reason for treatment failure. To solve this problem, clinical oncologist to a variety of solutions, is chosen in 2003 after the open literature on the following:

Tags: anti, cancer, carboplatin, cases, cell, cells, chemotherapy, cisplatin, clinical, csa, days, dose, drug, drugs, eat, head, injection, intravenous, method, ovarian, paclitaxel, patients, positive, rate, reduce, response, study, surgery, survival, therapy, time, toxicity, treatment

[Summary]

Ovarian cancer is a common cancer of female genital mutilation one of the incidence of cervical cancer and after cancer of the uterus, which ranked third. But ovarian cancer death, accounts of the first gynecologic tumors, right pose a serious threat to women's lives. Because ovarian embryonic development, organization anatomy and endocrine function more complicated, it may be suffering from benign tumors or malignant. Because of early ovarian cancer in asymptomatic, and the identification of its type benign and malignant very difficult, ovarian carcinoma laparotomy in ovarian tumor confined to only 30%, most have spread to the uterus, bilateral annex, the omentum and pelvic organs, both in the diagnosis of ovarian cancer and governance the treatment is a major problem indeed. Over the years experts on the pathological form of ovarian cancer, the development of clinical and treatment programs for many of accumulated a lot of experience, so far, statistics on domestic and foreign clinical data, the five-year survival rate of only 25% to 30%.

Tags: abdominal, age, amenorrhea, annex, anti, benign, bleeding, blood, body, cancer, carcinoma, care, cases, cause, cell, cells, chemotherapy, clinical, cyst, cystic, days, diagnosis, dose, drug, drugs, early, eat, ert, estrogen, examination, exploration, gene, grams, growth, gynecological, history, incidence, increased, injection, intraperitoneal, intravenous, irradiation, life, lymph, malignant, mass, metastasis, method, node, oppression, ovarian, ovary, pain, patients, pelvic, poor, prognosis, protein, radiation, radiotherapy, rate, reduce, resection, residual, screening, staging, surface, surgery, surgical, survival, symptoms, syndrome, therapy, time, toxicity, treatment, tumor, tumors, uterine, women

The choice of ovarian cancer surgery, chemotherapy and radiotherapy. But because of its pathological type complex, qualitative, without a diagnosis and staging laparoscopy or laparotomy, it is difficult clear. In addition to surgery is not generally the case or have the type of tumor in patients with systemic conditions not competent to surgery, chemotherapy or radiotherapy to trial again after surgery to consider, as appropriate, generally the preferred treatment. Surgical exploration can be further defined tumor types and scope of involvement, clear staging, not only for postoperative chemotherapy and radiotherapy provide basis, and possible removal of the tumor, chemotherapy or postoperative radiotherapy or create conditions to improve efficacy.

Tags: abdominal, age, annex, anti, body, cancer, cases, cause, chemotherapy, clinical, diagnosis, eat, examination, exploration, gene, irradiation, lymph, malignant, node, ovarian, patients, pelvic, poor, positive, radiation, radiotherapy, resection, response, second, staging, surgery, surgical, therapy, time, toxicity, treatment, tumor, tumors

One, paclitaxel and cisplatin in the treatment of advanced ovarian cancer care <BR> <BR> 1990s Taxol is more of the treatment of advanced ovarian cancer drug effective, and its unique mechanism is a new type of anti-tubulin role of antitumor drugs. Cisplatin for inorganic platinum metal complex, the cell cycle-specific drug, can inhibit DNA synthesis, combined with their synergies to enhance the effectiveness of [1]. In Division I from July 1996 to July 1998 to 15 cases of advanced ovarian cancer patients with Taxol and cisplatin in the treatment of satisfactory results.

One, information and Methods

Tags: administration, age, anti, blood, body, cancer, care, cases, cause, cell, cells, chemotherapy, cisplatin, clinical, confidence, days, diet, dose, drug, drugs, eat, ert, estrogen, family, fat, gene, group, growth, incidence, infusion, injection, intravenous, life, mass, metastasis, method, ovarian, paclitaxel, pain, patients, physical, poor, positive, psychological, quality, rate, reduce, response, skin, surface, surgery, survival, symptoms, taxol, therapy, time, toxicity, treatment, tumor, tumors, women

Clinical manifestations

(1) a <BR> symptoms, age occurred in perimenopausal women. Over more than 35 years of epithelial ovarian cancer, while those below the age of 35 occurred reproductive cell malignancies.
2, the pain may be due to malignant ovarian tumor of the changes, such as hemorrhage, necrosis, the rapid growth caused a considerable degree of persistent pain. The inspection found a local tenderness.
3, Irregular Menstruation see irregular bleeding, bleeding after menopause.
4, weight loss was sexually advanced thin.

Tags: abdominal, age, annex, anti, benign, bleeding, blood, body, cancer, cases, cause, cell, cells, chemotherapy, clinical, cyst, diagnosis, drug, drugs, eat, examination, exploration, fat, gene, growth, head, irradiation, life, lymph, malignant, mass, node, ovarian, pain, patients, pelvic, poor, positive, radiation, radiotherapy, resection, response, second, staging, surgery, surgical, symptoms, therapy, time, toxicity, treatment, tumor, tumors, women